Case Report: Immune dysregulation associated with long-lasting regression of a (pre)leukemic clone.

Autor:	Koedijk JB; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center (MC)/Sophia Children's Hospital, Rotterdam, Netherlands., van Beek TB; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Vermeulen MA; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Kester LA; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Schweighart EK; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Nierkens S; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands., Belderbos ME; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Zwaan CM; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Department of Pediatric Oncology, Erasmus Medical Center (MC)/Sophia Children's Hospital, Rotterdam, Netherlands., Heitink-Pollé KMJ; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Heidenreich O; Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.; Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Oct 16; Vol. 14, pp. 1280885. Date of Electronic Publication: 2023 Oct 16 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1280885
Abstrakt:	Regression of leukemia in the absence of disease-modifying therapy remains poorly understood, although immunological mechanisms are thought to play a role. Here, we present a unique case of a 17-year-old boy with immune dysregulation and long-lasting regression of a (pre)leukemic clone in the absence of disease-modifying therapy. Using molecular and immunological analyses, we identified bone marrow features associated with disease control and loss thereof. In addition, our case reveals that detection of certain fusion genes with hardly any blasts in the bone marrow may be indicative of an accompanying oncogenic fusion gene, with implications for disease surveillance- and management in future patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Koedijk, van Beek, Vermeulen, Kester, Schweighart, Nierkens, Belderbos, Zwaan, Heitink-Pollé and Heidenreich.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu